Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reddy’s and Hospira lose over US Alimta

Executive Summary

Dr Reddy’s Laboratories and Pfizer’s Hospira unit have suffered defeats in their US litigation over a vitamin regimen patent protecting Eli Lilly’s Alimta (pemetrexed disodium) injectable oncology drug. Lilly expects both of the generics companies to appeal against the ruling by the US district court for the Southern District of Indiana that the alternative salt forms of pemetrexed proposed by the generics firms would infringe US patent 7,772,209, which expires on 24 May 2022, including a six-month paediatric extension.

You may also be interested in...

Actavis Waits On Alimta Hybrid Following FDA Approval

FDA approval for a hybrid 505(b)(2) new drug application referencing Alimta has been awarded to Teva’s Actavis, with a key patent expiring in May 2022 proving a barrier to market entry. Teva was itself shot down over attempts to launch an ANDA product several years ago.

Supreme Court Refuses To Review Pemetrexed Case

The US Supreme Court has refused a certiorari petition to review a decision involving Dr Reddy’s and Pfizer over Eli Lilly’s Alimta that revolved around the doctrine of equivalents.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts